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LATE IN THE LEGISLATIVE SESSION of 1972 the H.R.l Bill 
amending Medicare-Medicaid was passed by Congress and signed into 
law by the President. The last provision of the act had a unique effect 
in that it "socialized" a common human disorder, chronic renal dis-
ease. Henceforth, according to the letter of this law, most victims of 
end-stage kidney disease, after 3 months of renal dialysis, can be 
treated under federal fiscal sponsorship by renal homotransplantation. 
The H.R.l legislation will give further impetus to the development 
of a field that has bloomed overnight on its own scientific merit. Conse-
quently, this monograph may be timely as new transplantation teams 
are formed to meet a predictably increasing demand. We will try to 
compress our own experience, which spans more than a decade and 
more than 500 transplantations, and from it draw conclusions for 
future guidance. To meet these objectives we have undertaken an up-
to-date evaluation of all patients in whom operation was performed 
before July, 1972. Follow-ups have been made current to September, 
1973. 
Based on this experience, a number of important and often contro-
versial issues will be examined, including variations in immunosuppres-
sive treatment with special reference to antilymphocyte globulin (ALG) 
and cyclophosphamide, tcchnical innovations and special surgical situ-
ations, the role of tissue typing, hyperacute rejection, organ procure-
ment and preservation, the problem of bone disease and hyperpara-
thyroidism after transplantation, the timing and results of retransplan-
tation, and recent changes in the interpretation of histopathologic 
changes in the homografts. 
EARLY TRIALS 
The specialty of organ transplantation is the most recently developed 
of the surgical disciplines, and is one that as a practical venture was 
considered highly improbable even 15 years ago.24 The observations 
that changed this point of view were made in most instances by clini-
cians who used the kidney homograft as their main experimental model 
in dogs and as their first clinical application. The principles delineated 
with the kidney were later applied, essentially without change, to the 
transplantation of other organs, including the liver, hcart and lung. In 
spite of the glamour of these latter efforts, the simpler kidney transplant 
still serves as the standard by which management policies involving 
This work was supported by research grants from the Denver Veterans Admin-
istration; by grants AI·AM·08898 and AM-07772 from the National Institutes of 
Health; and by grants RR-OOOSI and RR-00069 from the General Clinical Re-
search Centers Program of the Division of Research Resources, National Insti-
tutes of Health. 
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immunosuppression, tissue typing and other matters can be evaluated 
most precisely. . 
The Ii rst known attempts at clinical kidney transplantation by vas-
cular anastomoses were made without immunosuppression between 
1906 and 1923 with sheep,16; pig,l n3 goat l03 and subhuman pri-
mate215 , 2(;6 donors. None of the organs functioned, and the human re-
cipients died from a few hours to 9 days after transplantation. 
The first renal homotransplantation was reported in 1936 by Varo-
noy2'1 who transplanted a kidney from a cadaver donor of B+ blood 
type to a recipient of 0+ blood type in violation of what are now well-
accepted rules of tissue transfer (Table 1 )235 (see section on hyper-
acute rejection). Nevertheless, a few drops of initial urinary excretion 
were observed. The patient's death 48 hours after transplantation was 
attributed to a blood transfusion reaction. 
In the next 20 years sporadic additional trials were made without 
the benefit of effective immunosuppression, as recounted 10 years ago 
by Goodwin and Martin70 and more recently by Groth71 for the pur-
pose of recording historic landmarks. By 1951, Kiiss et al.128 and other 
members of the French school of surgery51. 55, 222 had virtually stan-
dardized the procedure of kidney transplantation to the iliac fossa, 
anastomosing the renal to the pelvic vessels of the recipient in much 
the same way as is practiced today. Despite the lack of success with 
these early patients, other cases were soon reported from Chicago, 129,130 
Boston,99. 100 Paris,151 Toronto,156 London104 and Cleveland.l22 
By the middle of the 1950s, the total number of attempts at human 
renal homotransplantation had reached approximately 30 without any 
immunosuppression at all, or with adrenocorticotropic hormone 
(ACTH) or cortisone in a few patients of Kiiss et al.,128 Dubost et 
al. 5 !, 55 and Hume et al.lOo Most of the homografts never had significant 
function, and those that did initially, usually underwent prompt rejec-
TABLE I.-DIRECTION OF ACCEPTABLE 
MISMATCHED TISSUE TRANSFER* 
o to non-O 
Rh- to Rh+ 
Rh+ to Rh-
A to non-A 
B to non-B 
AB to non-AB 
Safe 
Safe 
Relatively Safe 
Dangerous 
Dangerous 
Dangerous 
"The immunologic explanation for these rules 
is given in the section on hyperacute rejection. 
o is universal donor. AB is universal recipient. 
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vent prompt rejec-
tion, as was reported particularly clearly by Michon et al. l5l There were 
three more or less clear exceptions to this generalization. Renal homo-
grafts inserted by Lawler,l29. 130 Gordon Murray156 and HumelOO and 
their colleagues were said to have excreted urine for scveral months 
before being rejected slowly. The life of Hume's patient probably was 
increased thereby by several months. The unexpectedly prolonged sur-
vival of kidneys in untreated recipients has been cxplained since by the 
loss of immunologic reactivity that has been shown to accompany ure-
mia.44.112.155 
An intermediate era in clinical renal transplantation was begun in 
1958 by Joseph Murray and his associates159 at the Peter Bent Brigham 
Hospital with the use of total body irradiation as the primary means 
of immunosuppression. In the following 4 years, between 30 and 40 
renal recipients were treated primarily in this way, although in a few 
instances adjuvant therapy was added later with immunosuppressive 
agents such as 6-mercaptopurine. Almost all of these trials ended in 
the early death of the recipient, with the few notable exceptions re-
corded by Merrill,150 Hamburger,84. 8" Ktiss125-127 and Shaekman214 and 
their associates. Within 3 years, all but 2 of the patients were dead. 
Both of the exceptions, WllO were treated in Boston and Paris in 1958, 
were given kidneys from fraternal twins; they are stilI alive and are 
celebrating their fifteenth post-transplantation anniversaries in the sum-
mer and fall of 1974. i9 • 80. 157 
The most productive era of clinical transplantation began in 1962/ 
1963, and it is this period and the subsequent decade with which this 
monograph will be concerned. One factor contributing to the transplant 
"explosion" was the introduction of primary pharmacologic immuno-
suppression with the thiopurine compounds, 6-mercaptopurine and its 
imidazole derivative, azathioprine. These agents were developed by 
Dr. George H. Hitchings and his colleagues at Burroughs Wellcome and 
Company, Inc., Tuckahoe, New York, and found by them to inhibit 
hemagglutinin formation in mice challenged with heterologous red 
blood cells. 58. 90 Later, the effect of 6-mcrcaptopurinc and azathioprine 
in ameliorating rodent skin graft and canine kidney rejection was re-
ported by Schwartz and Dameshek218 and Calne,2728 respectively. As 
recounted by Groth,71 a number of patients in Europe and the United 
States were given one or the other of the mercaptopurine drugs between 
1959 and 1962, usually with a fatal outcome. However, 2 French re-
cipients survived for prolonged periods of time. One who lived for 17 
months was treated in 1960 by Kiiss and his colleaguesl26. 127 with 
6-mercaptopurine after initial total body irradiation, and the other was 
managed similarly by Hamburger and associates83 in January, 1962. 
Hamburger's patient, whose donor was a cousin, is still alive and is the 
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longest surviving non-twin recipient in the world.79 . 80 Murray et al.1 58 
reported the first patient in whom prolonged survival was achieved 
under primary immunosuppression with azathioprine alone; this recipi-
ent of a cadaver kidney lived for almost 2 years.1 61 However, even 
well into 1962, there was little evidence to indicate that drug therapy 
would yield results substantially better than those obtained with total 
body irradiation. 
Such improvements would await the administration of drugs in com-
bination (see later sections). The most important agent in such phar-
macologic cocktails has been prednisone and, as will be shown, it is the 
steroid rather than the 6-mercaptopurine or azathioprine component of 
combination drug therapy that has proved to be the only truly indis-
pensable element without which transplantation would not be practical. 
The experimental basis for the use of steroids to mitigate first-set rejec-
tion had been laid a decade earlier by Billingham, Krohn and Meda-
warI8 with prompt confirmation by others.29. 124. 148. 154. 234 Concerning 
second-set rejection, it was demonstrated by Krohn123 as early as 1954 
that cortisone acetate given to rabbits could abolish even a pre-existing 
state of sensitivity induced by full-thickness skin homografts. 
The other main immunosuppressants that have been used in drug 
combinations for whole-organ recipients are heterologous ALG and 
cyclophosphamide. The widespread use of these agents came later in 
the story of clinical transplantation and will be discussed in a subse-
quent section. 
DOUBLE DRUG THERAPY 
So far, attention has been focused upon some of the early clinical 
trials of immunosuppression with total body irradiation, steroids and 
the mercaptopurine drugs. With each of these agents, and for that mat-
ter with cyclophosphamide or heterologous ALG used alone, labora-
tory research has shown that a protracted and healthy life can be 
obtained for some canine kidney recipients. However, the consistency 
with which really long-term survival could be achieved was (and is) 
poor for the obvious reason that complete control of rejection usually 
was not possible with a single agent. Since the same kind of treatment 
failure was observed regularly in almost all of the early patients, there 
was little encouragement at first to undertake major clinical trials of 
renal transplantation. 
The most important development that made immunosuppression 
practical was the discovery of how azathioprine and prednisone could 
be used together advantageously. There were virtually no existing lab-
oratory data to indicate that the benefit of this now universally accepted 
combination of agents would be as great as it proved to be. Indeed, the 
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It is difficult even in retrospect to ascribe priority for azathioprine-
steroid therapy to any single authority or transplantation group. What 
is clear is that by late 1962 the two drugs were being used together at 
our center244 and by Hume et al. 98 at the Medical College of Virginia 
with great enthusiasm about their synergism in the prevention or re-
versal of renal homograft rejection. Murrayl61 and Woodruff288 and 
their colleagues also reported giving steroids to some of their patients 
in less regular and less well-defined regimens. Since then, the double 
drug program of azathioprine and prednisone has become standard 
therapy throughout the world. Some authorities do not believe that fur-
ther changes in this regimen (such as the addition of ALG) are nec-
essary. 
THE TIMING OF AZATHIOPRINE-STEROID THERAPY 
At our center double drug treatment has been provided in two ways. 
In both, azathioprine was started shortly before operation and con-
tinued indefinitely thereafter, generally in the maximum doses thought 
to be possible without causing leUkopenia. Prednisone was used either 
prophylactically, beginning on the day before or the day of operation, 
or it was withheld until the onset of a clinically evident rejection. From 
our own experience, the technics and drawbacks of both approaches 
were analyzed several years ago.235 In retrospect, the most important 
advantage of withholding steroids until graft repudiation clearly had 
started was that the features of rejection and host-graft adaptation as 
well as the influence of drug therapy on these processes could be de-
lineated with some precision. The greatest disadvantage was that the 
rejections that developed under treatment with azathioprine alone were 
sometimes very severe and difficult to reverse with delayed steroid ther-
apy. It was found that their incidence and severity were reduced if 
prednisone was given from the beginning.235 Consequently, it has been 
our policy since December, 1963, to treat virtually all recipients of 
organ homografts with both drugs from the outset. 
In 1967, Kountz and Cohnl20 reported that azathioprine and predni-
sone delivered suddenly into the arterial supply of renal homografts had 
an increased protective effect on the organs as compared to that ob-
tained with oral or intravenous administration. The steroid amounts 
were very large, and it soon became obvious that this dose factor rather 
than the route of administration was the most important therapeutic 
influence. Subsequently, many centers have reported that by giving 
large intermittent doses (up to 2 gm) of corticosteroid, the daily main-
tenance steroid requirements can be reduced. 35, 236, O~RK 289 
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THE REVERSAL OF REJECTION 
The use of the double drug programs promptly led to one of the most 
important contributions of clinicians: the demonstration that rejection 
is a highly reversible process. This concept had not emerged from the 
skin graft experiments upon which the foundations of transplantation 
biology were largely based, nor was it evident in the first trials of either 
canine or human renal homotransplantation. 
In retrospect, it is probable that the Boston and Paris fraternal twins 
mentioned earlier both passed through rejection crises. The events in 
Hamburger's caseS5 were the clearest. For almost 3 weeks after opera-
tion the transplanted kidney functioned perfectly. Fever, azotemia and 
proteinuria then developed, but within a 1 O-day period these symptoms 
receded without the institution of any specific therapy. Hamburger 
ascribed the changes to the spontaneous reversal of an immunologic 
crisis. 
Evaluation of the course in Merrill's case150 was made difficult by 
complicating circumstances. Although immediate good renal function 
was obtained also, within a few weeks fever and a rise in BUN level 
were seen, but at the same time the patient's own kidneys had cortical 
and perinephric abscesses. After nephrectomies and drainage had been 
carried out, the deterioration was reversed and Merrill concluded that 
"the oliguria and nitrogen retention ... were clearly associated with an 
episode of infection." Eight months later, a biopsy of the homograft 
revealed mononuclear cell invasion and other morphologic evidence of 
chronic rejection. Although function was stable and essentially normal, 
additional total body irradiation was given as well as a course of adrenal 
corticosteroids. At the time that these observations were reported, Mer-
rill and his associates believed that a rejection had been "aborted" 
thereby. In commenting on the significance and the earlier timing of 
events in Hamburger's case, Merrill expressed doubt that rejection had 
occurred in the French patient, saying that "it seems highly unlikely ... 
that in a partially tolerant patient, rejection would begin at the time at 
which it might be expected for the non-tolerant person, only to abort 
spontaneously. " 
The first suggestion that rejection is a highly controllable and re-
versible phenomenon came from our own observations in 10 patients 
treated in late 1962 and early 1963.244 In 7 patients, clear-cut rejection 
of variable intensity occurred from 4-34 days after operation (Fig. 1), 
leading in one case to anuria. In each instance the process was reversed 
by the addition of massive doses of prednisone to the pre-existing aza-
thioprine therapy (Fig. 1). Three of these 7 patents are still alive more 
than a decade later and are now among the longest-living recipients of 
non-twin homografts in the world. After the remarkable effectiveness 
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FIG, I.-Classical rejection crisis in a patient from Series I treated initially with 
azathioprine (Imumn) alone. Deterioration of renal function began J 9 days after 
transplantation. All stigmata of rejection were present except for acute hyperten-
sion and weight gain, which were successfully prevented by medical treatment. 
With the addition of prednisone the rejection crisis swiftly resolved. A eli-C, Acti-
nomycin-C; LN, left nephrectomy at time of transplantation; RN, right nephrec-
tomy. (From Starzl, T. E., e/ al.2H ) 
of steroid therapy in this situation had been established from our own 
experience, but before our findings were published, it was learned that 
the same kind of rejection reversal with steroids had been achieved by 
Goodwin and his associates G8 in a young woman whose other main drug 
was cyclophosphamide and who ultimately died of sepsis 144 days after 
receiving a maternal homograft. 
It was realized also almost from the beginning~PR that a reduction in 
9 
homograft blood flow is an integral component of rejection crises and 
that the pham1acologically induced reversal is accompanied by relief 
of organ ischemia. Both conclusions have been supported by animal 
experiments.66, 201. 206 
GRAFT "ACCEPTANCE" 
The reversibility of rejection was only one of the features that estab-
lished the clinical feasibility of organ transplantation. The quantities 
of adrenal corticosteroids necessary to achieve reversal were often ex-
tremely large and too toxic to be compatible with long survival of the 
recipient if continued indefinitely. Fortunately, another event of equal 
practical importance transpired coincidentally with or shortly after the 
reversal of rejection. The need for intensive immunosuppressive ther-
apy usually diminished with the passage of time both in patients who 
did and those who did not pass through a cliniCally evident rejection. 
Thus, the patient whose course is depicted in Figure 1 had returned 
within 5 months after transplantation to treatment only with azathio-
prine, the drug that initially had not prevented the onset of a moder-
ately severe rejection. An ultimate, similar reduction in drug require-
ment is seen today in almost all new cases although it is known now 
that there are but few occasions when steroid therapy may be stopped 
completely. Even so, it is probable that some patients eventually could 
have all therapy discontinued. In our laboratory, dogs that were given 
treatment with immunosuppressants for only the first 4 months after 
receipt of life-sustaining liver or renal homografts from nonrelated 
mongrel donors are living almost 10 years later.235 • 236 
Although it has been well established that a homograft may come to 
be more or less tolerated in its new host, the explanation for the privi-
leged status is by no means clear, perhaps because more than one 
immunologic pathway may be involved. 
SPECIFIC IMMUNOLOGIC TOLERANCE.-Probably, the continuous 
presence of a transplanted organ in a host being treated with immuno-
suppressive therapy often leads to a selective loss of responsiveness to 
the antigens of the homograft (tolerance). The evidence that chemo-
therapy can be used for the induction of narrow-range tolerance is un-
equivocal, as has been summarized by Schwartz.217. 219 Experimentally, 
azathioprine, 6-mercaptopurine, amethopterin, cyclophosphamide and 
even total body irradiation can be used to promote specific tolerance, 
provided the antigen in question is administered in an appropriate dose 
and in close temporal approximation to the immunosuppressive 
treatment. 
One of the theories that has been advanced to explain the specific 
effect of chemotherapy under these circumstances is depicted in Fig-
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ure 2.217 ,219,235,236 The drawing suggests that a clone of lymphocytes 
that presumably have an active metabolism as the'result of stimulation 
by antigen should be differentially susceptible to killing by antimetabo-
lites. That such an effect could be attained without the need to induce 
leukopenia implies that specific abrogation of the host immune re-
sponse is achievable under the conditions of clinical transplantation' 
even though nonspecific immunosuppressive agents are employed, 
The concept of "clone stripping" in the scheme of Figure 2 is con-
sistent with the cyclic phenomena that occur characteristically after 
whole-organ transplantation in treated recipients, But whether and 
with what frequency human recipients of renal homografts actually 
establish tolerance to their donor tissue has not been established se-
curely. One reason has been the potential risk that could attend some 
of the testing, such as skin transplantation, required to prove this pos-
sibility. In dogs this has been said to precipitate the rejection of pre-
FIG. 2.-Hypothetical mechanisms by which nonspecific immunosuppression 
may lead to selective abrogation of the host immune response, Special suscepti-
bility to these agents of a fraction of the lymphoid population could lead to ex-
haustion of a clone and, hence, tolerance. Since maintenance of such cell lines 
even in adult life is apparently thymic.dependent in experimental animals, thy-
mectomy would be expected to aid the process; this appears to be true in rodents, 
but the effect of thymus removal in man has not been shown to be an overriding 
factor. A possible protective role is shown also of immunoglobulins elaborated 
by the replicating cells. Conceivably, the antibodies could act at several sites. See 
text for discussion. (From Starzl, T. E.236) 
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viously well-established canine renal grafts. 162 However, Amos and 
Bach l have performed mixed lymphocyte culture examinations from 
the peripheral blood of a number of the recipients in our hospital and 
their donors 2-4 years after transplantation. In some patients in whom 
clear donor-recipient histocompatibilities were detectable by serologic 
typing, they found that the recipient lymphocytes no longer underwent 
blast transformation when exposed to killed donor white cells, although 
they reacted vigorously to third-party lymphocytes. 4 The findings, 
which were interpreted as indicating specific acquired immunologic 
tolerance, have been confirmed in patients studied in other cen-
ters, 12.227 but the frequency of this happy occurrence is not known. 
ENHANCEMENT.-It was shown by Kaliss107 that homografted tissue 
in tumor systems may be protected by the presence of certain kinds of 
antigraft antibodies. It is conceivable that by a feedback mechanism of 
protective blocking antibodies or antigen-antibody complexes, the 
same thing occurs under the conditions of whole-organ transplanta-
tion. The process could be envisioned as shown in Figure 2, whereby 
antigraft immunoglobulins synthesized by the activated clone either 
shield the target tissue from killer lymphoid cells (local enhancement) 
or prevent the immune processes from proceeding normally at some 
more distant site (central enhancement). 20.63.282 
COMBINATION MECHANISMS.-Of course, it is unnecessary to char-
acterize graft acceptance with a single explanation, whether this be 
narrow range tolerance, the action of blocking antibodies (enhance-
ment) or some additional but less formally stated possibility (ies) . 
Traditionally, the two immunologic mechanisms of tolerance and en-
hancement have been separated very strictly from each other. The jus-
tification for this recently has been summarized brilliantly by Meda-
war,]4, who at the same time pointed out that an "either-or" attitude 
was not necessary to explain graft survival under a wide range of ex-
perimental circumstances, especially if a state of partial tolerance were 
involved. 
There is no doubt that the conditions for successful renal transplan-
tation are complex and vary from case to case. An unstable situation 
of partial tolerance is probably common, with significant inactivation 
of the cell lines involved in cell-bound immunologic response but with 
retention of some antibody responses as depicted in Figure 2. How 
this might be achieved presumably would depend upon the fortuitous 
choosing of the right dose, aggregation form and administration route 
of the transplant antigens, to say nothing of the immunosuppressive 
treatment. Although such factors can be demonstrated readily to be 
instmmental in inbred animal strains, they can be studied only irregu-
larly and at random in outbred animal populations, including man. 
Recent publications from Seattle by Pierce184 and Quadracci,198 
working with the Hellstroms and Marchioro, have offered hope of dis-
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1d Quadracci,198 
ered hope of dis-
entangling the complex and obviously dynamic processes of human 
homograft acceptance in individual patients. Using the cell inhibition 
assay of Hellstrom and Hellstrom,8i Pierce and Quadracci demon-
strated that blood lymphoid cells capable of exerting a cytotoxic effect 
against donor target cells were very common early after transplantation 
but often were accompanied by serum-blocking factors (antibodies?) 
that could cancel the expected harmful effect. By the end of the first 
year, in successful cases the reactive lymphocytes tended to disappear 
as one might expect with the gradual induction of tolerance. However, 
the findings were highly variable from case to case and at different 
times in the same recipient. 
THE DURABILITY OF "ACCEPTED" HUMAN HOMOGRAFTS 
AFTER DOUBLE DRUG THERAPY 
Updated reports about patients provided with renal homografts early 
in the so-called modern era of organ transplantation are still of vital 
current interest since these are the only data from which an idea of the 
long-term prognosis of more recently treated and still surviving pa-
tients can be obtained. Consequently, a series of 64 consecutive pa-
tients treated in Denver by our group with azathioprine-prednisone 
therapy between the autumn of 1962 and March, 1964, is particularly 
useful. This was the first series in which a large number of patients 
were brought through the first few postoperative months successfully. 
Those from the original group who are still alive now have follow-ups 
of 9 1/2 to almost 11 years. 
There were 46 recipients of consanguineous kidneys from 23 sib-
lings, 20 parents, one aunt, one uncle and one cousin, and 18 recipi-
ents of nonrelated kidneys donated by healthy volunteers. In 45 
patients azathioprine was started alone (Fig. 1); with the appearance 
of clinically obvious rejection, prednisone was added in 43 of these 
45 patients. In the other 19 recipients both drugs were administered 
from the outset. 
Typing procedures were not available when this series was com-
piled. Consequently, the donor-recipient matching was not done by any 
kind of immunologic guidelines except for the avoidance in all patients 
(after Case 23) of the kind of red blood cell type incompatibility that 
can lead to hyperacute rejection (Table 1). ParentheticaIIy, one of our 
earliest patients, an A + type recipient, is still alive with perfect graft 
function 10 years and 8 months after transplantation from a B+ type 
donor, a combination that no longer would be used. 
All of the recipients had splenectomy. The first 8 (of whom 4 are 
still living) had pre transplantation thymectomy. Nine additional pa-
tients had thymectomy 81/z-17 months after transplantation in the 
hope of reducing the need for immunosuppression. Five of the 9 recipi-
13 
~----- --~I-- ------
10 
Related Cases 
p~rtes 1 0----0 46 Potienls 
Series :r _____ 25 PO!lenls 
Unrelated Coses 
Series I 0- _ - - 0() 18 Pollenls 
Ser;es n ... __ _ .. 23 Pollents 
~ 
Z 
> 6 :; 
a: , ::> 
U) .5 ~ 
2 
, 
~ 
.... -, 
,--,I=--_ (21124) 
II (9/11) 
\....--""--
9 .4 
.... 
, 
I-~ 
.. ---.., 
0-, 
.. - -- --~ 
u 
..: .3 
a: 
"-
.2 
.1 
.. ~ 
.. ---... II (3/5) I .. ________________ .. ' , 
~- --~ 
... -------~I I (112) 
~------------------------------~ 
o+----K----~--_Ir_--_K----r_--_I----r_--_r----r_--_r--­
o 2 3 4 5 6 7 8 9 10 
TIME IN YEARS 
FIG. 3.-The life survival curves of 112 recipients treated between November, 
1962, and April, 1966, with the double drug program of azathioprine and predni-
sone. Series I was compiled between November, 1962, and March, 1964, so the 
potential follow-ups are 91;2 to almost 11 years. Series II was compiled from 
October, 1964, to April, 1966, permitting follow-ups of 71/2-9 years. All of the 
nonrelated donors in Series I were volunteers. Of the 23 nonrelated donors of 
Serie" II, 17 were volunteers; the other 6 were cadavers. The main difference 
between Series 1 and II was that pro,pective HL-A typing was attempted in Series 
II. At the end of each curve, the denominator shows the number of patients still 
alive. The numerator indicates the number of original kidneys still functioning. 
Only one of the surviving patients is on dialysis (a member of unrelated Series II). 
The other recipients whose kidneys have failed have had successful retransplanta-
tion, usually under one of the triple drug treatment regimens that included ALG. 
ents are still alive but 3 of them have undergone retransplantation. 
Although thymectomy may have a significant effect in human beings, 
as will be discussed later, it is no longer performed in our center. 
SURVIVAL AFTER 46 RELATED TRANSPLANTATIONS.-After a heavy 
mortality (33%) in the first 6 months, subsequent deaths have been 
uncommon (Fig. 3). Of the 31 recipients who survived a half year, 
29 lived for 3 years, 28 for 5 years, and 24 (52 % ) are still alive after 
9'h to almost 11 years. None is now on dialysis, and 21 of the 24 have 
function of their original grafts; the other 3 had retransplantations 5'h, 
5%, and 7 years after the first procedure. The secondary kidneys have 
functioned subsequently for 51;3 and 4% years in the first 2 of these 
retransplanted recipients. The third one is now living on his fifth kid-
ney. The problem of retransplantation will be considered in a later 
section. 
The outcome was not influenced strikingly by the nature of the 
donor relationship (parent, sibling or other) (Table 2). The parent-
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to-offspring results were amazingly stable in temlS of recipient survival. 
At the end of 6 months, 14 (70%) of 20 recipients were alive. By 
9 1/2-11 years there were still 13 (65%) alive, although 3 of these 
survived by virtue of retransplantation. Also of interest was the fact 
that all of the 3 distantly related renal grafts (aunt, uncle and cousin) 
were providing superb function nearly a decade after their insertion. 
The causes of mortality in the first 5-year follow-up of this series 
have been reported exhaustively. 235. 247 They usual1y involved infec-
tion, renal failure or both (see Fig. 7). Therefore, only the four deaths 
in the second 5 years will be mentioned. Two patients with adequate 
renal function 8V4 and 9 years post-transplantation died of chronic 
aggressive hepatitis of several years' duration; one was Australia anti-
gen positive. A third patient had a fatal myocardial infarction after 
7Y.3 years, and the fourth patient had a technically unsuccessful re-
transplantation in the sixth year and then committed suicide by refus-
ing to be placed back on hemodialysis. 
Half of the original series of related kidney recipients are entering 
or already have entered into the second decade of their convalescence. 
SURVIVAL AFTER 18 UNRELATED TRANSPLANTATIONS.-Two thirds 
of the recipients died in the first year, and the mortality rose until only 
2 patients were left at the 5-year mark (Fig. 3). These 2 are still alive 
after 9V2 and 9 213 years, but in one instance a second homograft from 
the mother has supported life for the last 6 years of the total survival. 
The poorer results in nonrelated transplantation would have been 
discouraging were it not for the great progress made in many centers, 
including our own, with cadaver transplantation (see later section) 
since the spring of ] 964, when this series was completed. 
GRAFT FUNCTION AND IMMUNOSUPPRESsION.-Table 3 shows the 
average renal function in September, 1972, of the 22 survivors whose 
first and only homografts had functioned at that time for 8Y2 to nearly 
10 years. The data have not changed substantially since then. The im-
munosuppression given chronically to those patients also is listed. The 
average daily doses of prednisone are small enough to avoid a Cush-
ing's facies. 
Arterial hypertension is an almost universal finding in the immediate 
posttransplantation period and even for several years afterward.235 • 247 
This problem has tended to diminish with longer follow-up, and none 
of the 22 patients with original homografts has significant hypertension. 
At the time that the foregoing data were collected, the 4 patients 
who were (and still are) living after retransplantation had less favor-
able functional results, with follow-ups after retransplantation of O~-
7 years. In September, 1972, their BUN levels were 39 ± ] 8.5 mg/l 00 
ml, and their creatinine clearances were 60 ± 33 ml/min. One of the 
latter recipients is severely hypertensive. 
16 
TABLE3.-A 
RECIPIENT 
FROM I 
PATIENT 
LD 2 
LD 3 
LD 6 
LD 12 
LD 13 
LD 14 
LD 17 
LD22 
LD25 
LD 33 
LD34 
F 
(m 
LD 37 1 
LD 39 1 
LD42 1 
LD49 2 
LD 51 2 
LD 52 1 
LD53 2 
LD55 2 
LD 58 1 
LD60 4 
LD 63t O~ 
Mean±SDof22 
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-The data were compi! 
Four additional patien 
to fifth grafts. Sec text fOI 
tSufviving recipient of 
The degree of re 
All who were adu 
some kind of full-1 
than 18 years (ran! 
all have returned t 
follow-up was org. 
ported themselves 
patient who had sp' 
a child, first treatel 
and who subsequer 
years old and is stl 
f recipient survival. 
'nts were alive. By 
Ithough 3 of these 
terest was the fact 
uncle and cousin) 
'ler their insertion. 
w-up of this series 
1Iy involved infec-
nly the four deaths 
ents with adequate 
m died of chronic 
,vas Australia anti-
ial infarction after 
:y unsuccessful re-
d suicide by refus-
pients are entering 
leir convalescence. 
IONS.-Two thirds 
llity rose until only 
:ese 2 are still alive 
1d homograft from 
, the total survival. 
would have been 
e in many centers, 
:see later section) 
deted. 
Table 3 shows the 
~O survivors whose 
e for 8 Y2 to nearly 
ince then. The im-
; also is listed. The 
1 to avoid a Cush-
Ig in the immediate 
rs afterward.235 • 247 
.\low-up, and none 
!cant hypertension. 
ted, the 4 patients 
on had less favor-
plantation of 2%-
~9 ± 18.5 mg/100 
JI/min. One of the 
TABLE 3.-AvERAGE RENAL FUNCTION AND IMMUNOSUPPRESSION IN 22 
RECIPIENTS SCk\l\I:-;G 9'/2-11 YE\RS AFTER TRANSPLANTATION 
FROM LIn:-:G DO:-:ORS AND WITIl CONTINUING FUNCTION 
01' THE ORIGINAL HOMOGRAFT* 
SERUM 
BUN CREATTNII"E CREATININE 
(mg/IOO (mg1100 CLEARANCE AZATHIOPRINE PRED:-';YSO'1"E 
PATlENT ml) ml) (ml/min) (mg/day) (mg/day) 
LD 2 16 1.7 70 100 0 
LD 3 11 1.1 130 150 0 
LD 6 20 1.3 105 200 10 
LD 12 18 1.4 70 100 15 
LD 13 19 1.4 90 87.5 7.5 
LD 14 10 0.9 120 200 0 
LD 17 9 0.8 70 100 2.5 
LD22 17 0.8 90 137,5 10 
LD 25 22 1.6 80 50 10 
LD 33 12 1.2 90 125 0 
LD34 31 1.5 60 50 0 
LD 37 11 1.0 94 150 15 
LD 39 17 1.0 80 125 10 
LD42 18 1.1 75 125 7.5 
LD49 25 1.1 70 87.5 5 
LD 51 21 1.3 85 125 10 
LD 52 17 0.8 110 150 5 
LD53 25 1.6 55 100 5 
LD55 27 1.4 40 150 20 
LD 58 16 1.4 65 137.5 10 
LD60 46 3.3 40 87.5 20 
LD 63t 27 1.4 80 125 15 
Mean ± SD of 22 
original grafts 19.8::':::8.3 1.3±0.5 80.4 ±22.9 121.0::1:: 38.8 8.1±6.3 
'The data were compiled in September, 1972. but have not changed significantly since then. 
Four additional patients in this 1962-1964 series are still alive but are living on their second 
to fifth grafts. See text for renal function of the latter patients, 
tSufviving recipient of living unreJated renal homograft. 
The degree of rehabilitation in the group has been truly remarkable. 
All who were adults at the time of transplantation have returned to 
some kind of full-time work. Of the 12 survivors who were younger 
than 18 years (range 3-17 years) at the time of the original operation, 
all have returned to school. By September, 1972, when a full social 
follow-up was organized,75 half had graduated from college, 8 sup-
ported themselves fully in adult work and 9 had married. The only 
patient who had spent an excessive amount of time in the hospital was 
a child, first treated at the age of 3, whose original homograft failed 
and who subsequently required four retransplantations. He is now 13 
years old and is stunted in growth. His prognosis for reaching emo-
17 
tional anu physical maturity is doubtful although his present condition 
is highly satisfactory. 
At the time of this original series potential recipients were screened 
with great care to rule out those with possible important psychiatric 
problems. Because of this it is not surprising to find exceptional emo-
tional stability among those who were accepted and who are still sur-
viving. Excellent adjustments have been made in spite of serious early 
postoperative complications such as aseptic necrosis of one or both 
femoral heads in 3 of the adolescents. These 3 patients have learned 
to walk adequately in spite of their handicaps. Many of the young 
patients were stunted in growth before and after their transplantations 
but have had catch-up growth spurts late in their teens (Fig. 4). 
Nine of the 64 patients in the original series had had children of 
their own by September, 1972, 3 by 2 female recipients, and 10 by 7 
male recipients. One of the offspring had a meningomyelocele that re-
quired operative correction; no other birth defects have been recorded. 
It is of interest that all of the children issuing from this transplant popu-
lation came from the 26 recipients still surviving. Thus, no orphans 
have been created so far by the premature death in Series I of a trans-
plant patient. 
It is fair to say that no new difficulties ever were encountered in our 
extensive subsequent experience that had not been defined by the time 
the foregoing series was closed out in March, 1964. A number of these 
FIG. 4.-The height percentile growth curve in a 10·year-old girl who was far 
below the third percentile at the time of renal homotransplantation. After opera-
tion. steroids were tapered gradually. She did not reach the fiftieth height per-
centile until the fifth year after transplantation. She is now 20 years old and a 
college student. (From Pediatrics, 47: 548, 1971). 
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problems will be discussed in a later section, including special techni-
cal surgical hazards, requirements of retransplantation and the effect 
of chronic immunosuppression in increasing the risk of cancer. 
FURTHER EXPERIENCE WITH THE DOUBLE 
DRUG REGIMEN 
When the original series of patients on double drugs was completed 
in March, 1964, a 6-month moratorium was called for two purposes. 
First, we felt obliged to establish the general pattern of the life survival 
curve before undertaking a new series of renal transplantations. During 
the moratorium it became clear that very important prolongation of 
recipient life would be obtained, thereby justifying further trials. 
Second, we hoped to find a better means of biologic selection of the 
donor than the essentially random method that had been necessary up 
to this time. A collaboration was established with Dr. Paul Terasaki of 
Los Angeles, from which eventually came the first prospective trial of 
HL-A typing. 262 When clinical activities were resumed in October, 
1964, which continued until April, 1966, an effort was made in almost 
every case of this Series II to find the most HL-A compatible donor 
from available volunteers. For the consanguineous transplantations 
the selectivity usually was limited, and in a number of instances there 
was only one possible organ volunteer. This made it difficult to upgrade 
substantially the average matches in comparison to those achieved be-
fore by chance, as judged by a retrospective study of surviving pa-
tients from Series 1. In contrast, the first 17 recipients of nonrelated 
kidneys had their donors selected with considerably increased discrimi-
nation by HL-A matching of from a few to as many as almost 100 
penal volunteers. The last 6 patients in the unrelated Series II received 
unmatched cadaver organs. 
It was a great disappointment that the results in Series II \vere so 
little affected by prospective HL-A typing, a subject to which we will 
return. Now, with a follow-up of from 71h to almost 9 years, the life 
survival curve after consanguineous transplantation is actually poorer 
than that with the randomly selected donors of Series I (Fig. 3). Only 
11 of the 25 related recipients are still alive, 9 with continuing function 
of their first grafts. To compensate, there has been a slight improve-
ment in the life survival curve after nonrelated transplantation (Fi¥. 3). 
However, in both groups the actual changes in re~ults of the 1964-1966 
versus the 1962-1964 era were not statisticaIly significant. 
It is possible, especially in related cases, lhat the deterioration of 
results in Series II was due to relaxation of the very stringent require-
ments for admission to the program that were enforced at the begin-
ning. Thus, more patients at high risk were accepted. 
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TRIPLE DRUG THERAPY INCLUDING AlG 
The justification for adding further therapeutic adjuncts to azathio-
prine and prednisone was that the patient mortality or kidney loss rate 
appeared, at least in our hands, already to have reached an irreducible 
minimum by the spring of 1964 when Series 1I was completed. As just 
recounted, the results in the ensuing 2 years ( 1964-1966) of Series II 
had not been improved substantially in spite of the increased experi-
ence acquired. 
This experience resulted in a change in timing but not in the ultimate 
incidence of failure. During the learning period, when azathioprine and 
prednisone first were used together, there were a number of deaths 
from drug toxicity during the early postoperative period. Many of these 
fatalities were due to bone marrow depression caused by overdoses of 
azathioprine. A common course was that good initial kidney function 
was obtained from the homograft, a severe rejection crisis then super-
vened with a secondary return of uremia, and leUkopenia and lethal 
sepsis followed shortly thereafter. 235 At least part of the explanation 
was thought to be that the renal pathway of detoxification of azathio-
prine had been lost to a variable degree as a consequence of rejection. 
The practice was developed of considerably reducing the azathioprine 
doses under these circumstances or after poor initial function of cadav-
eric homografts had been observed. Bach and Dardenne,9 in subse-
quent studies, could find no good evidence that poor renal function 
changes the proper dose of azathioprine, but in spite of their interest-
ing publication we have continued to exercise great restraint in the 
azathioprine doses prescribed during secondary renal failure. With 
this cautious attitude, practiced at our center for almost 10 years, the 
complication of bone marrow depression has been largely eliminated. 
Avoidance of the hazards of chronic steroid therapy was less simple. 
Indeed, the side-effects of prednisone seemed even more numerous and 
severe with the increased conservatism in azathioprine dosage. In many 
cases of both Series r and II, continued function of the transplanted 
kidneys proved to be dependent upon the chronic administration of 
unacceptably large quantities of prednisone. The delayed complica-
tions that often followed ranged from the exceedingly troublesome to 
the lethal. They included cosmetic deformity, bone demineralization, 
muscle wasting, arrest of growth in infants, fatty infiltration of the liver, 
pancreatitis and gastrointestinal ulceration and hemorrhage. Most seri-
ous, however, was the resulting susceptibility to infection with micro-
organisms of all types. 
If the consequent infections were due to common pathogenic bac-
teria, usually they could be treated successfully with properly chosen 
antibiotics. Very often, however, they were caused by fungi, protozoa 
or viruses for which specific therapy was not available. The manifesta-
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tion of this sequence of events in a series of autopsies on renal trans-
plant recipients at our institution has been summarized by Hill et alKU~ 
A difficult therapeutic dilemma often was posed by the foregoing 
situation with either intrafamilial or cadaveric transplantation, but far 
more commonly after the latter. On the one hand, life was threatened 
by reduced or failing function of the homograft, and on the other, by 
the immunosuppressive measures taken to prevent further deteriora-
tion or complete loss of the graft. One of the great lessons learned in 
the field of rcnal transplantation has been that there arc very material 
benefits of retransplantation with or without removal of the first homo-
graft. An alternative approach would be to deliver more effective and 
less toxic early postoperative immunosuppressive therapy during that 
critical time when graft acceptance is hoped for. It was with this objec-
tive that heterologous ALG was added as a third agent in almost all 
clinical cases after May, 1966. 
THE THERAPEUTIC SCHEDULE 
The fascinating history of antilymphocyte serum (ALS) and its 
globulin fraction (ALG) has been recapitulated in a recent text. 236 
The first investigators to demonstrate the ability of ALS therapy to 
mitigate skin homograft rejection were Waksman, Arbouys and Arna-
son,2i2 who in 1961 observed a weak but statistically significant effect 
in guinea pigs. The subsequent investigations of Woodruff and Ander-
son287 catalyzed widespread interest in such antisera by demonstrating 
a striking protection of homografts in rats treated with ALS alone or 
in combination with thoracic duct drainage. Within 2 years, antisera of 
comparable or greater potency for use in mice or rats were developed 
by many other investigators. By 1966, a beneficial effect of ALS after 
whole-organ transplantation had been demonstrated in our laboratory 
and elsewhere in mongrel dogs. These intermediate steps in large ani-
mals were necessary to determine the most effective and least toxic 
therapeutic schedules and to evolve practical technics of administration 
acceptable for use in man. This kind of information was sought in dogs 
by use of heterologous ALS raised in horses, sheep or rabbits. The 
regimen of ALG that was used in man eventually was guided by the 
following conclusions that emerged from these large animal experi-
ments23(;: (l) ALG has potent but imperfect immunosuppressive 
qualities when used alone. (2) With cOI1tinued administration of the 
heterologous serum derivatives there is a highly significant risk from a 
variety of foreigl). protein reactions including anaphylaxis. (3) ALG 
can be used effectively and probably with increased safety in combina-
tion with other drugs. 
Each of these factors contributed to the initial decision to employ 
heterologous ALG as an adjuvant agent combined with azathioprine 
21 
and prednisone and to limit its use to the first 4 postoperative months. 
It was hoped that the predictability and safety with which homograft 
rejection could be prevented would be improved thereby and that the 
hazards of immunologic reactions to the serum product would be re-
duced in accordance with thc emcient level of immunosuppression to 
which all three agents would contribute. 
TREATMENT PROGRAM IN THE FIRST CAsEs.-The way in which this 
policy decision was translated into the treatment program2%. 242, 248 is 
shown in Figure 5. Daily intramuscular injections of ammonium-
sulfate-precipitated ALG prepared from horse serum were started sev-
eral days before operation, continued for the first 10-14 days after-
ward and then progressively reduced to every other day, twice a week 
and once a week in the ensuing 3 Yz months. Azathioprine was begun 
on the day of operation and continued indefinitely. Prednisone therapy 
was either instituted immediately or, in a few cases, withheld until 
onset of rejection or the appearance of serologic evidence of antibody 
formation against the injected ALG (Fig. 5). 
In these first cases the dose of the immune globulin for adults was 
FIG. 5.-The postoperative course of a patient who received ALG before and 
for the first 3112 months after renal homotransplantation. The donor was an older 
brother. There was no early rejection. Prednisone therapy was started 40 days 
postoperatively because of high rises in the serologic titers that indicated a host 
response against the injected ALG and warned against a possible anaphylactic 
reaction. By our present policy steroid therapy would be started at the same time 
as the ALG. Note the insidious onset of late rejection after cessation of globulin 
therapy. This was treated by increasing the maintenance dose of steroids. (From 
Surg. Gynecol. Obstet. 126: 1023,1968). 
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usually 4 ml. The injectate had leukoagglutinin and Iymphocytotoxicity 
titers of 1: 4,000 to 1: 16,000 and a protein content of 4.6 to 9: 3 
gm/ 1 00 m!. Significant lymphopenia was not always produced. Usu-
ally, the fraction of lymphocytes in the peripheral smear was reduced, 
but a leukocytosis also occurred, and the total peripheral lymphocyte 
count was relatively unchanged. Nevertheless, a striking immunosup-
pressive effect was detectable during the pretransplantation period 
when no other immunosuppressants had been started. Many of the 
recipients had positive skin tests to tuberculin, histoplasmin or other 
allergens. These became negative when the patient was retested 48-72 
hours after the institution of globulin therapy, indicating that the ALG 
prevented expression of previously established delayed hypersensi-
tivity. 
ADJUSTMENTS OF TREATMENT PROGRAM TN SUBSEQUENT CASES.-
ALG has now been used at the University of Colorado for more than 
7 years. In a few cases and for special indications the raw antiserum 
has been obtained from rabbits or goats; however, the usual source of 
ALG in our program has been the horse. From 1966 to 1971, the ani-
mals were chronically immunized with splenic lymphocytes obtained 
from human cadavers. Beginning in 1971, the cultured Iymphoblasts 
introduced by Najarian and his colleagues 166 were used for the anti-
gen, thereby permitting a much more standard producti2 to be raised 
by acute immunization. 
At present, the schedule of ALG recommended for our patients dif-
fers only in a few details from that originally introduced. The last 4- to 
6-\veek period, during which the injections were given once or twice 
a week, has been eliminated, so the usual duration of globulin therapy 
now is about 2 months. The antilymphoblast globulin now employed 
is made up to a standard concentration of 5 gm % rather than the pre-
vious wide range of protein content being permitted. With Groth's 
schedule of immunizationi2 antiwhite cell (leukoagglutinin and Iym-
phocytotoxicity) titers as well as rosette inhibition titers of 1: 8,000 to 
1: 32,000 are predictably obtainable. 
CLINICAL RESULTS 
FIRST TRIALs.-Beginning in June, 1966, when ALG was intro-
duced clinically, and continuing to the spring of 1968, a total of 77 
patients were treated with renal transplantation (Series III, Fig. 6). 
The donors for 60 of these recipients were related family members. 
The other 17 kidneys were taken from cadavers, usually under condi-
tions of brain death rather than cessation of cardiac activity. Except 
for some sibling cases, the results of HL-A matching were no longer 
followed in donor selection, which consequently reverted to a nearly 
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FIG. 6.-The life survival curves of 214 patients treated between June, 1966, 
and March, 1971, with the triple drug program of azathioprine, prednisone and 
heterologous ALG. All of the nonrelated donors were cadavers. Since Series II[ 
was completed by the ,pring of 1968, a minimal potential follow-up of 51;2 years 
is available for the 51 surviving recipients. Series IV was completed by March, 
1971, permitting a minimum potential follow-up in these patients of about 3 years. 
Thus, the life survival curves in the related cases of Series IV from the point of 
the arrow to the fifth year is the best that could be achieved provided no further 
deaths occur in the final 2-year interval. This latter life survival curve is the only 
one either in this illustration or in Figure 3 that is not essentially complete as 
depicted. 
The main distinction between Series III and IV was that recipient selection was 
liberalized greatly in the later period, so the previous contraindications of age, 
concomitant systemic disea5e and certain kinds of renal or urinary tract disease 
were largely removed. The numerator, which indicates the number of original 
kidneys still functioning, and the denominator, which indicates the number of 
patients still alive, at the end of the curves have the same significance as in Fig-
ure 3. Only 1 of the 145 patients who are still alive is presently on hemodialysis; 
128 have continuing function of their original grafts and the other 16 have been 
retransplanted successfully. 
random process. The results from this series have been reported on 
several occasions, most recently in 1970.w In September, 1973, there 
were follow-ups in the remaining patients ranging from almost 5Y2 to 
more than 7 years. 
Observations of the 60 related cases of Series III have supported the 
attitude that renal transplantation no longer can be considered an ex-
perimental clinical procedure. Of the 60 recipients the survivals are: 
1 year-55 (92%)' 2 years-53 (88%), 3 years-51 (85%), 4 
years-47 (78%) and 5 years-46 (77%). At the present time, 45 
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he present time, 45 
(75%) of the patients are living 51h years or more postoperatively. 
Furthermore, 42 of the 45 surviving patients (70% of the original 60) 
still have function of their first transplants. These results constitute an 
improvement over our 1962-1966 experience in that there \vere more 
kidneys and more patients left after 51/2-7 years than had remained at 
the end of the first year in either Series I or II. 
The results were also improved substantially in the 17 unrelated 
(cadaveric) organ recipients of Series III. There were 14 (82 %) and 
13 (76%) of the patients still alive at the end of the first and second 
post-transplantation years. However, unlike the situation after con-
sanguineous transplantation, the losses continued at a brisk rate through 
the third, fourth and fifth post-transplantation years. By the end of 5 
years there were only 6 survivors (35 % ). All 6 still have life-sustain-
ing function of their original homografts. 
Although the mortality was lower, the causes of death in the triple 
drug, ALG-treated patients of Series III were not very different from 
those encountered in the double drug era of Series I and II. In the 
spring of 1970, the data from all of the unsuccessful cases were exam-
ined. At that time, 79 of the 189 patients who made up the three series 
had died, 40 after receiving related kidneys and 39 after receiving non-
related organs. Autopsies \vere performed in all but 2. In reviewing the 
causes of the 79 deaths, a specific notation was made in every case 
about the roles of renal insufficiency and infection in the fatal outcome. 
Two associations were obvious. First, 68 of the 79 patients had less 
than normal (42 examples) or failed (26 examples) renal function in 
the interval before death (Fig. 7). Second, a major infectious compli-
FIG. 7.-The contribution of imperfect or failed renal function and of infec-
tions to the deaths of 79 patients. The shading of symbols indicates that infection 
either caused or was a major contributor to death. The squares indicate excellent 
premortem renal fUIlction, the tria/1gles indicate subnormal but life-supporting 
premortem renal function and the circles indicate that the homografts had failed. 
(From Starzl, T. E., et al.: Ann. Surg. 172 :437, 1970). 
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cation \vas present in 58 (73%) of the patients (Fig. 7). As discussed 
carlier, the most difticult therapeutic dilemma was posed by the co-
existence of variable degrees of renal impairment in conjunction with 
sepsis. In 53 (70%) of the deaths the combination of imperfect (or 
failed) homograft function and infection was present. 
The timing of death differed in the three periods of our experience. 
In Series I the mortality was heavily concentrated in the first 3 months 
(Figs. 3 and 7), largely due to a tendency to administer doses of aza-
thioprine that caused bone marrow depression, especially when renal 
impairment was present. In Series II this error was avoided. However, 
the mortality from infection was not prevented but only postponed to 
the 4- to 12-month post-transplantation period (Figs. 3 and 7). With 
the more balanced form of immunosuppression used in Series III the 
deaths became rather evenly distributed throughout the first 2 years 
(Figs. 6 and 7). Half of the patients in the last series had significant 
infection at the time of death, compared to 80% and 76% in Series I 
and II. 
The locations of the infections were highly variable, but the most 
common were the lung (31 cases), the central nen'ous system (5 brain' 
abscesses and 3 meningitides), the transplant wound (8) and the peri-
toneal cavity (4). The infecting microorganisms \vere frequently mul-
tiple, but it was usually possible to determine the dominant agent. 
Deaths in the first 3 months were due mainly to well-known bacteria 
such as Pseudomonas acruginosG, Escherichia coli and Staphylococclls 
aureus (Table 4). After the early post-transplantation period, nonbac-
terial (fungal, protozoan or viral) infection played a major role 
(Table 4). Between the fourth and twelfth months after transplanta-
tion Pnellmocystis carinii accounted for 5 deaths, and fungal infections 
killed an additional 5 patients. After 4 months 4 patients died from 
viral causes alone, 3 with viral hepatitis and the fourth with pan-
intestinal varicella. Multi-organ cytomegalic inclusion disease was 
found in many patients, often in association with Pnelll1locystis carillii. 
There were 2 deaths in the early postoperative period from acute 
pancreatitis. Pulmonary emboli were the cause of death in 3 patients 
(after 3, 1U~/O and 28lhmonths) and contributed to the death of at 
least 10 others. Two recipients aged 37 and 41 died of myocardial in-
farction 21h and 4113 years post-transplantation. Reticulum cell sar-
coma accounted for 2 late deaths. Other causes of mortality in single 
cases included suicide, inanition, stroke and jejunal necrosis. 
The foregoing list of complications, which spans our total experience 
up until 3 years ago, has been presented in detail for two reasons. 
First, it provides a realistic cross-section of the hazards of major sur-
gery under immunosuppressive therapy with or without recurrence of 
uremia. Second, it indicates that the problems caused by immuno-
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TABLE 4.-PATHOGENIC ORGANISMS INVOLVED IN 
THE DEATHS OF 79 PATTENTS* 
NUMBER OF PATIENTS 
DYI"G OF INFECTION AT 
Over 
0-3 4--12 12 
Months Months Months 
BACTERIAL 
Staphylococcus aureus 3 4 2 
Hemolytic Streptococcus 4 0 0 
Listeria monoc)'togelles 0 1 0 
Diplococclls pllell17l0lliae 1 0 0 
Escherichia coli 8 1 2 
Pseudomonas ae/'llginosa 12 8 5 
Klebsiella aerobacter 4 1 2 
Proteus mirabilis 3 0 0 
Paracolon species 1 0 0 
VIRAL 
Hepatitis 0 1 2 
Cytomegalic inclusion disease 3 1 2 
Varicella 0 0 1 
PROTOZOAN 
Pneul710cystis carinii 8 
FUNGAL 
Aspergillus jllmigatlls 2 3 2 
Candida albicans and 
C. stellatoidea 4 2 1 
Nocardia 0 2 0 
Histoplasmosis 0 1 0 
Cryptococcus 0 0 1 
'Some patients died with 2-3 types of microorganisms. For each patient the 
full spectrum of clinically significant microbiologic data has been entered into 
the table. 
suppression are apt to be troublesome and of the same general kind 
with a wide range of regimens. Thus, no single agent or combinaton of 
agents now in use can be viewed as a panacea. 
LATER CASEs.-From March, 1968, until March, 1971, 137 fresh 
cases were added to the drug combination trial of azathioprine, predni-
sone and ALG, creating a Series IV with present follow-ups ranging 
from 211z -5 th years. The donors for 122 of the patients were blood 
relatives, and the organs for the other 15 were taken from cadavers. 
The small number of new cadaveric cases was because most of the 
available cadaver kidneys were being used to carry out retransplanta-
tions upon recipients whose first grafts were failing or had failed. This 
special subject wiII be discussed later. HL-A typing was not a major 
factor in donor-recipient matching except for A-matched siblings. 
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There were some features of Series IV that distinguished it from 
Series III. First, a number of the criteria by which patients formerly 
were excluded from treatment by transplantation had been progres-
sively eroded; thus, there were increasing numbers of recipients over 
the age of 45 years who had diseases of other organ systems, including 
the heart, or who for other reasons such as prior malignancy, diabetes 
mellitus or systemic lupus erythematosis previously would have been 
considered excessively high risks. Second, there was a change in the 
ALG used midway through Series IV from that raised with immuniza-
tion by cadaveric spleen cells to that raised with immunization by 
lymphoblasts. Finally, the number of surgeons and physicians operat-
ing upon and taking care of the growing colony of transplantation pa-
tients increased. To some extent the degree of personal attention that 
could be given to every patient by a small and highly experienced team 
was lost, with a consequent greater dependence upon therapeutic 
formulas. 
The results in the related donor component of Series IV were less 
favorable than in Series III. The life-survival curves in Series IV are 
complete to almost 3 years. At 3 years the patient survival is 71 %, 
compared to 82 % in Series III. It is certain that a disparity in results 
of approximately the same magnitude will persist through at least the 
fifth year (Fig. 6). 
So far, the results in a small series of cadaveric transplantations in 
Series IV have been superior in terms of patient survival. Twelve 
(80% ) of the 15 recipients are still alive with follow-ups exceeding 3 
years in 11 of the patients and 2% years in the twelfth. The reason for 
the high patient survival was our readiness to carry out retransplanta-
tion with or without removal of the first homograft, as has been 
strongly advised by Hume97 and Kountz l18 and their associates. Only 6 
of the 12 remaining patients have continued function of their original 
homografts. However, none of the other 6 is on dialysis since all have 
undergone successful retransplantation. 
THE IMPORTANCE OF ALG AND OTHER QUESTIONS 
In December, 1971, and late April, 1972, two working conferences 
on the clinical use of ALG were convened-the first in San Diego and 
the second in Bad Soden, Germany. The discussions and formal papers 
from the European workshop have been published220 and are availabJe 
for those who wish to peruse the details from which the following sum-
mary has been drawn. 
First, it was disconcerting to realize from these two meetings the 
extent to which many central and practical questions about ALG had 
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yet to be answered. Some of these questions have been clarified at least 
partially but others have not. 
There is probably not an appropriately informed, responsible scien-
tist in the world who does not concede that ALG is a potent immuno-
suppressive agent in man; but that is not the question perplexing clini-
cians interested in renal transplantation. Rather, the issue is whether or 
not ALG fills some unique role that cannot be met equally well by the 
clever manipulation of other agents such as steroids, azathioprine and 
cyclophosphamide. Opinions about this vary even today. At the Bad 
Soden conference, testimony about the value of ALG in renal trans-
plantation was given from 13 centers. Representatives from eight 
thought ALG was valuable, but four clinicians did not believe that 
their results were improved by it, and one European surgeon thought 
they actually might have worsened. The only controlled study of ALG 
in cadaveric renal transplantation yet performed224 was brought up to 
date by Dr. Ross Sheil of Australia. His patients, who received a 
2-month course of goat ALG in addition to maintenance therapy with 
azathioprine and prednisone, fared better than those who did not get 
ALG. However, the differences were not overwhelming. Consequently, 
this ,small series. important and wisely planned as it was, must now 
have corroboration. Although we ourselves have resisted thus far the 
compilation of a control series without ALG because of our conviction 
of its value, we would support strongly anyone wishing to carry out 
such a controlled study and are now considering this possibility our-
selves. 
The question of indispensability of ALG must be settled because of 
the tremendous im'estmcnt of personnel and material resources re-
quired to make ALG available for human use. We have heard of ex-
amples in which the cost of ALG accounted for half of the financial 
investment in the treatment of a renal recipient. The expertise required 
to ensure a supply is considerable. These efforts and expenses will be 
worthwhile only if tangible and substantial benefits are demonstrable. 
In addition to the labor of procuring ALG there are potential dan-
gers in its administration. Anaphylaxis, \\hich has led to several deaths 
(including two at our institution), is the most terrifying side-effect, but 
there arc others, including injection site pain and thrombocytopenia. 
Injury to the homograft itself by the development of serum-sickness 
nephritis has been reported, but we have not seen this. The University 
of Minnesota group has reported serious thrombotic complications 
with a high titer ALG given intravenously at their center and else-
where. Apparently these thrombotic calamities were caused by cross-
reactions of the antiwhite cell antibodies with recipient platelets. 
If the results of future controlled clinical trials prove to be positive, 
29 
it will be an enormous stimulus for commercial drug companies to go 
into production, and the consumer cost should then fall. Even if highly 
successful clinical transplantation trials are carried out, major prob-
lems of standardization will remain. There are four exceptionally sen-
sitive points that must be clarified: (1) the best animal in which to 
raise ALS, (2) the most effective immunization schedule, (3) the cor-
rect antigen and (4) the in vitro and in vivo technics for evaluating the 
effcctiveness of the product. 
The choice of an animal probably is not a crucial factor provided 
certain rules are followed. 286 • 220 The schedule of immunization also is 
not critical except that if the course is short and standard, the ultimate 
product is apt to be relatively the same from animal to animal. In 
horses in our laboratory Groth et al.'2 have shown that the use of 5 or 6 
accurately timed pulses with large doses of Iymphoblasts almost always 
gives an essentially identical response curve. 
The third question-the best antigen source-is still open for dis-
cussion. The thymocyte has a number of advocates in spite of the 
demonstration of Ono et al.1;0 that a variety of lymphoid organs are 
about equal in their ability to raise potent ALG. From the viewpoint of 
convenience and purity a strong contender is the cultured lymphoblast, 
which, as far as we know, represents a pure p-cell population. Within 
the next few months we plan to begin a contro][ed study comparing 
horse ALG raised with thymocyte membranes to that raised with cul-
tured lymphobla5ts. 
As to the fourth point, there has been a gradual acceptance of at 
least three in vitro tests. Even a year ago there were flat denials that 
the leukoagglutinin and Iymphocytotoxicity titers had any correlation 
with immunosuppressive effect, although it was commonly asserted 
that correlations were good with the rosette inhibition test of Bach et 
al.10 At the Bad Soden meeting good correlations were reported with 
all three of these tests as well as with several new ones. With this kind 
of information it should be possible to establish dose schedules for ALG 
that would make its use as a traditional drug possible. 
In reviewing our experience of the last decade it is obvious that ALG 
is not an absolutely indispensable drug without which clinical trans-
plantation would be impossible; nor, for that matter, is azathioprine, 
which can be replaced by cyclophosphamide. The only agents that 
occupy this role are the adrenal corticosteroids, of \vhich prednisone 
has been used most widely. Without the adrenal corticosteroids we be-
lieve that the management and reversal of rejection would be so seldom 
achievable that the clinical discipline of renal transplantation would 
vanish. 
It is in this context that ALG must be evaluated. We have always 
considered it an adjuvant immunosuppressant that is of the greatest 
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value for short-term use during the often difficult early postoperative 
period when the issue of graft acceptance or failure is decided most 
commonly. When viewed in this way, we have been convinced that 
ALG is an important part of our therapeutic armamentarium and has 
improved not only survival but also the quality of convalesccnce. 
TRIPLE DRUG THERAPY INCLUDING 
CYCLOPHOSPHAMIDE 
During the 9 years starting in 1962, only three major immunosup-
pressants were used extensively for whole-organ transplantation: aza-
thioprine, prednisone and heterologous ALG. None of these agents is 
suffiCiently potent to permit consistent success when used alone in 
human beings. Consequently, the drugs have been administered in the 
double combination of azathioprine and prednisone or the more recent 
triple combination of all three agents. Since March, 1971, we have had 
extensive expericnce with a fourth major immunosuppressive drug, 
cyclophosphamide ECytoxan~FI which we have given instead of aza-
thioprine to most recipients of a primary transplantation for a variable 
portion of the early postoperative period.238. 240, 249 
EARLY BACKGROUND 
In retrospect, it is surprising that cyclophosphamide has played such 
a trivial role in the transplantation of whole human organs, since the 
drug has been known for more than a decade to possess strong immu-
nosuppressive properties. 140 • 2:;0. 254 Moreover, the animal research sup-
porting this contention has been reviewed and updated frequently.16. 21, 
62,64.106,l'3.2Jl Virtually alI of the encouraging laboratory investi-
gations were done in mice, rats or other rodents or in rabbits. Unfor-
tunately, when cyclophosphamide was tested in the dog renal or 
intestinal transplantation model as an intermediate step to clinical 
application, either no prolongation of graft survival was obtained or 
else the effect was minor. l9G • 200. 292 It may be suggested now that the 
dampening influence of the discouraging canine experiments was based 
upon a species difference that made the dog an inappropriate animal to 
evaluate cyclophosphamide for human immunosuppression. 
Despite the experience in dogs there has been evidence in man sup-
porting the propriety'of testing cyclophosphamide for clinical whole-
organ transplantation. Some of this information came from efforts to 
promote tolerance to bone marrow grafts, as proposed by Santos and 
coIleagues210• 213 anl'i subsequently carried out by several other work-
ers. Prodigious doses of cyclophosphamide (45-100 mg/kg/day) 
were given, but only for a few days, in close temporal approximation 
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to infusion of homologous bone marrow. Although such efforts repre-
sent an essentially different therapeutic approach from ours, it is worth 
emphasizing that Santos's data on several immunosuppressive drugs 
have indicated that, in man, cyclophosphamide is superior to most 
other agents and is at least equal to azathioprine. 210• 212 
In the early days of renal transplantation, immunosuppression with 
cyclophosphamide was tried in a few cases. Almost 10 years ago, 
Goodwin et al. 69 treated a renal recipient with cyclophosphamide plus 
prednisone; good kidney function was maintained during much of the 
144 days of post-transplantation life. Shortly afterward, Parsons/i5 
Fox62 and others reported 4 patients with cadaveric renal transplanta~ 
tion in whom cyclophosphamide was given as the sole therapy. One 
patient died after a technical surgical accident, and a second died from 
infection after 33 days. The other 2 recipients lived for 8 and 23 
months, respectively, a feat that in our experience can be achieved only 
rarely with azathioprine or any other single agent after renal transplan-
tation from a nonrelative. 235 However, in a follow-up of these 2 pa-
tients and 4 more who survived for only a few days, Parsons et al. 
pessimistically advised against further clinical trials of cyclophospha-
mide. 1i4 
It is regrettable that these early efforts at renal transplantation under 
cyclophosphamide therapy were made when the conditions were not 
more propitious. Specifically, it was then believed that the deliberate 
production of leukopenia was desirable, whereas now we hold such a 
policy to be dangerous and unnecessary. Moreover, as already im-
plied, the importance of combination drug therapy was not yet fully 
appreciated. In our own trial cyclophosphamide was used with two 
other potent immunosuppressants, prednisone and ALG, and against 
a background of considerable experience with multiple drug treatment. 
THE COLORADO TRIALS 
With consanguineous transplantation, administration of cyclophos-
phamide, prednisone and horse antilymphocyte ALG was started sev-
eral days before operation and continued afterward, as in the triple 
drug regimen described earlier (Figs. 8 and 9). q~e first patients in this 
study were treated with cyclophosphamide for many months, after 
which a change was made eventually in almost every case to mainte-
nance therapy with azathioprine (Fig. 8). In contrast, patients treated 
in the last portion of the study, to be reported below, had a shorter 
course of cyclophosphamide therapy (l-2 months) before being 
switched to azathioprine (Fig. 9). The results were essentially the 
same with either variation. The dose of cyclophosphamide (in mg/kg) 
was usually one half to two thirds of that later used for azathioprine in 
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FIG. S.-The chronic use of cyclophosphamide in conjunction with prednisone 
and early ALG in the recipient of a parental renal homograft. Treatment was 
changed to azathioprine after 10 months with an increase in the mg/day dose. 
The patient has a perfect result after 211'2 years. (From Starzl, T. E., el al.238 ) 
the same patient. With both of these potentially radiomimetic agents 
an effort was made to avoid leukopenia . 
Therapy after cadaveric transplantation was similar to that after 
consanguineous transplantation, but immunosuppressive pretreatment 
was not feasible. 
RESULTS AFTER RELATED TRANSPLANTATION.-For the 44 recipi-
FIG. 9.-The use of cyclophosphamide for the first postoperative month with 
subsequent azathioprine treatment. The result is excellent after 2 years. (From 
Starzl, T. E., e I alPS) 
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ents the donors included 24 siblings (9 HL-A double haplotype iden-
tical), 17 parents, one aunt, one cousin and one grandmother. Except 
in sibling cases, the HL-A matching was not taken into account in the 
donor selection. The patients were treated from March, 1971, to July 
10,1972, assuring a minimum follow-up of 14 months and a maximum 
observation period of 2 V2 years. 
The life survival curve in this Series V is shown in Figure 10. Of 
these related recipients 36 (82%) are alive and 34 (77%) still have 
function of their original grafts. The results were approximately the 
same as had been achieved in the last with similar case material and 
azathioprine as the primary cytotoxic drug. 
RESULTS AFTER CADAVERIC TRANSPLANTATION.-After 16-30 
months, 21 (75%) of the 28 recipients are alive and 17 (61%) still 
have life-supporting function of their first cadaveric kidney (Fig. 10). 
The results were comparable to those obtained earlier with the original 
triple drug program that did not contain cyclophosphamide. 
DELAYED CYCLOPHOSPHAMIDE THERAPY.-In addition to the fore-
going experience with new cases, observations have been made with 
late substitution of cyclophosphamide for azathioprine. This was done 
FIG. 1O.-Life survival curves of 72 patients submitted to primary renal trans-
plantation under the triple drug program of cyclophosphamide, prednisone and 
ALG shown in Figures 8 and 9. A month or more postoperatively, cyclophos-
phamide usually was replaced by azathioprine for chronic maintenance therapy. 
All recipients have follow-ups of at least the duration indicated by the arrows. 
All unrelated organs were cadaveric. The numerators and denominators at the 
end of the curves have the same significance as in Figures 3 and 6. Note that the 
time scale (abscissa) is different from those in Figures 3 and 6. 
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in 49 rcnal recipients from I1h-94 months postoperatively,249 In 11 
patients hepatotoxicity or other side-effects of azathioprine, including 
drug fever, were suspected. Nine more patients were switched to cyclo-
phosphamide because of the serologic diagnosis of chronic Australia 
antigenemia even though abnormalities in liver function were either 
minimal or absent. The switch in therapy in the other 29 patients was 
made in the hope of eventually maintaining graft function with smaller 
dosages of prednisone. Consequently, reductions in the daily quantities 
of steroids usually were made shortly after the institution of cyclo-
phosphamide. 
In replacing azathioprine with cyclophosphamide, the same precau-
tions were taken as when cyclophosphamide was used from the begin-
ning. Frequent white blood cell counts were obtained, and appropriate 
dosage adjustments were made with any indication of impending leuko-
penia. It was found possible to maintain the typical patient on a per-
kilogram dosage of cyclophosphamide one half to two thirds of that 
previously tolerated for azathioprine. 
The details of this substitution trial have been reported. 249 Since the 
ALG injections usually had been stopped earlier, the drug switch in 
most patients was made when the only other immunosuppressive'agent 
being used was prednisone. After the drug change the clinical course 
'usually was not obviously different from that preceding the substitution. 
In a few instances in which hepatic dysfunction or fever were present, 
these abnormalites receded. The studies demonstrated once more, and 
in a very straightforward way, that cyclophosphamide is an immuno-
suppressant with a potency, safety and therapeutic role similar to that 
of azathioprine, at least for short-term therapy. 
PRACTICAL AND THEORETIC IMPLICATIONS 
The remarkably comparable effectiveness of cyclophosphamide and 
azathioprine under the aforementioned general conditions of clinical 
testing is of some theoretic interest since they belong to different chemi-
cal families and because their phannacoJogic actions are thought to be 
dissimilar. Yet, the events of rejection, its reversibility and eventually 
the feasibility in many instances of lightening maintenance immuno-
suppression have not been perceptibly different in the two drugs. It 
remains to be seen whether or not switching agents will have real bene-
fits that might be realized if, for example, the depletion of sensitized 
immunocompetent cells were made more complete thereby. At the 
moment this remains a possibility for which there is as yet no solid 
evidence. 
At our center we continue to use cyclophosphamide as our first cyto-
toxic drug, changing to azathioprine after 1-2 months. However, the 
essentially similar results after renal transplantation under primary 
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FIG. 11.-The course of a 17-year-old girl in whom azathioprine was stopped 
because of the suspicion of hepatotoxicity and fever. ~lultiple Australia antigen 
tests for semm hepatitis were negative. Note the recession of jaundice after the 
substitution of cyclophosphamide for azathioprine. l\fore than a year later, aza-
thioprine was reinstituted with recurrence of the manifestations of the same tox-
icity which receded again under cyclophosphamide. BUS, blood urea nitrogen 
level. SGOT, serum glutamic oxalacetic transaminase in international units, W BC, 
white blood cell count. (From Starzl. T. E., e/ (1/,24')), 
cyclophosphamide, as opposed to azathioprine therapy, will not be a 
strong inducement for other groups to change their present regimen of 
azathioprine management except for special indications, Even though 
we have treated patients daily with cyclophosphamide for as long as 
2 \/z years, we prefer to switch to azathioprine e\'entually for main-
tenance, based on our expaience of this drug's remarkable safety in 
many patients over the span of a decade, 
However, one special indication for use of cyclophosphamide chroni-
cally, instead of azathioprine, is the suspicion of specific toxicity of the 
latter agent. In several of our patients derangements in liver function 
were in'iproved thereby, and in a few others unexplained high fever 
has disappeared within a few days. The patient whose course is shown 
in Figure 11 had liver function abnormalities and fe\-ef, both of which 
receded with substitution of cyclophosphamide for azathioprine. More 
than a year later, a switch back to azathioprine was made with recur-
rence of these symptoms, which once again reversed under cyclophos-
phamide, 
Because of its relative freedom from causing hepatotoxicity, \ve tend 
to use cyclophosphamide for somewhat longer periods for our liver 
transplant recipients,Z38 
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HYPERACUTE REJ ECTION 
HL-A typing was one of the principal research interests of the Colo-
rado transplantation team, in collaboration with Dr. Paul Terasaki of 
Los Angeles, in the mid-J960s. Unfortunately, the evaluation of human 
histocompatibility matching in renal transplant recipients has not been 
possible with anything like the precision of a controlled laboratory 
experiment. One reason was that varying degrees of patient presensi-
tization may occur to antigens present in the eventual organ donor. The 
consequence of this unfavorable condition may be an accelerated or 
even a hyperacute rejection in spite of an apparently good histocom-
patibility match. The following remarks will summarize what has been 
learned of this disastrous complication and the mechanisms leading to 
its development. 
THE ROLE OF PREFORMED ANTIBODIES 
ABO INCOMPATIBILITY.-The first clear examples of hyperacute 
rejection of renal homografts were observed in patients who had re-
ceived kidneys from ABO blood group incompatible donors.235 An 
effective blood ftow to some of these transplants was not restored when 
the vascular anastomoses were opened. Angiography demonstrated the 
small vessels of the excised kidneys to be closed and, histopathologi-
cally, the arterioles and capillaries were plugged with formed blood 
elements, particularly erythrocytes (see section on pathology). 
A rational, although partial, immunologic explanation was available 
since the blood group substances that allow red cells to be typed are 
found also in other tissues, including the kidneys.91. 205 Consequently, 
if the kidney of an A, B or AB donor were placed in a patient whose 
serum contained naturally occurring anti-A and/or anti-B isoagglu-
tinins (e.g., a recipient with 0 blood type who would have both kinds 
of isoagglutinins), these antibodies might be predicted to bind with the 
renal red cell antigens. Serologic studies in some of our patients 'showed 
that falls in systemic isoagglutinin titers actually occurred,235 suggesting 
their depletion by such an antigen-antibody reaction. Subsequent 
authors have reached similar conclusions about the role of red cell iso-
agglutinins in precipitating accelerated rejections. 225 
PRESENSITIZATION.-Hyperacute rejection in the presence of red 
cell group compatibility has been seen with increasing frequency, and, 
in fact, this kind of rejection has become a major cause of acute homo-
graft loss in many transplantation centers. The first case was described 
by Terasaki and associates257 in a patient whose serum contained lym-
phocytotoxic antibodies that killed donor cells. The recipient appar-
ently had been immunized accidentally to white cells that shared 
histocompatibility antigens with the eventual renal donor. This concept 
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of prcsensitization has been supported indirectly by the high rate of 
hyperacute rejection with retransplantation in patients whose first 
homografts were rejected and who presumably ,vere immunized there-
by to some antigens also present in the second graft. 
Subsequently, Kissmeyer-Nielsen and his associates 114 and many 
other authors39• 163. 231. 2,]1. 261. 216. O~U have confirmed the adverse impli-
cations of preformed antidonor antibodies as detected with several 
technics. The methods most commonly employed have measured lym-
phocytotoxins and leukongglutinins, but the most sensitive examina-
tion has been said by Williams et al.2i6 and Klassen and Milgromll7 to 
be the mixed agglutination test. In our laboratories231 deliberate sensi-
tization of dogs by repeated skin grafts led to the formation of a variety 
of antibodies, each with antidonor reactivity. However, the titer of 
these antibodies is not well correlated with the rapidity of rejection of 
a kidney from the skin donor. Moreover, it has been emphasized in 
reports of clinical cases231 • 2-11 that hyperacute rejection may occur even 
though antidonor antibodies in the recipient serum cannot be found 
with any currently available technic, including the mixed agglutination 
method. Under these circumstances it has been necessary to assume 
that an immediate, albeit undiscernible, immunologic reaction is the 
initiating event in the destructive process that follows. 
VASCULAR OCCLUSION BY FORMED BLOOD 
ELEMENTS AND COAGULATION 
One view of hyperacute rejection might be that anti donor antibodies 
destroy renal homografts by their direct nephrotoxicity or toxic effects 
on vascular endothelium. However, the process is not this simple even 
though clearance of the antibodies by the stricken organ can be demon-
strated easily.J9. 231. 237 
The evidence has been growing for several years that coagulation 
changes are an integral feature of the hyperacute rejection caused by 
preformed antibodies in the presensitized canine model231 as well as in 
man.237 In dogs receiving multiple skin grafts from the eventual organ 
donor, the subsequently tramplanted kidney, spleen or liver always 
consumed clotting factors, platelets and other formed blood elements 
locally. One of the objectives of these animal investigations was to see 
whether or not transplantation of consecutive organs from the same 
donor would mitigate the rejection of the second graft. It was found 
that the second transplant was protected briefly, possibly by the prior 
depletion of humoral antibodies, clotting factors, formed blood ele-
ments or possibly all of these. In time, however, the final organ suffered 
the same fate as the first one. 
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All of the sensitized canine recipients in the above study231 devel-
oped evidence of local consumption of clotting factors. In addition, a 
minority of animals also had profound systemic coagulation changes 
that were like those of disseminated intravascular coagulation (DIC). 
The same kind of observation has been made in patients after renal 
homotransplantation with a subsequent severe or even fatal bleeding 
diathesis.163.237 TIme;, although the clotting aberrations of hyperacute 
rejection usualIy are confined to the graft insofar as can be measured, 
there is now little reason to doubt that profound systemic changes may 
follow. 
White cells, platelets and red cells also are cleared by hyperacutely 
rejecting homografts and form a morphologically prominent compo-
nent of the vascular plugS. 19 . 231.237 Williams et al. 278 were the first to 
draw attention to the dramatic appearance of polymorphonuclear leu-
kocytes (PMN) in such kidneys. Their observations, which since have 
been confirmed, were made possible by systematically doing biopsies of 
homografts about I hour after revascularization. In some instances the 
PMNs appeared before any other histopathologic findings were evi-
dent. That the participation of these cells in the ultimate destruction 
was not immunologically specific was illustrated by the canine experi-
ments of Clark34 and Robertshaw204 and their associates that showed 
that autologous PMNs were effective intermediaries of hyperacute re-
jection. The recent studies of cat-to-dog lung xenografts by Cook et 
al. 4o have shown how the vascular plugging in hyperacute rejection may 
proceed, at least in this model, with red cells before the aggregation of 
white cells. 
THERAPEUTIC POSSIBILITIES 
Although the factors contributing to hyperacute rejection (especiaIly 
presensitization) have been well defined, the precise mechanism of the 
destructive process remains obscure, In particular, the interlocking 
pathogenetic relationships of antibodies, formed blood elements and 
clotting factors have not been well defined. However, because of the 
existence of these interrelationships, two general lines of therapy have 
been investigated. First, attempts have been made with a variety of 
anticoagulants to interfere with the coagulation process. Second, efforts 
have been made to deplete the preformed antibodies or to prevent their 
action with use of ,complement inhibitors or organ pretreatment with 
digested antidonor immunoglobulin.42 
All therapeutic trials so far in human beings with presensitization 
states have failed. Hyperacute rejection remains one of the unsolved 
problems in the field of renal transplantation. 
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HL-A TISSUE TYPING 
After having completed a survey of our clinical experience, it now 
will be useful to describe our investigations of HL-A tissue typing. The 
use of these technics for their possible value in more rational donor-
recipient pairing occupied our attention soon after the inception of the 
Colorado transplantation program, and our interest has continued until 
the present time. However, by the time Series III had been completed, 
it was already apparent that the initial great expectations of simple 
HL-A typing were not going to be realized. 
The only ground rule that was followed for donor-recipient immu-
nologic matching during the compilation of Series I during 1962-1964 
was avoidance of the red blood cell incompatibilities summarized in 
Table 1. By the spring of 1964, considerable interest had developed in 
the serologic detection of lymphocyte antigens20S as a measure of histo-
compatibility determinants in the kind of matching that since has been 
widely employed. 3• 30.31, 43.46. 116. 119. 256.209.260.268 Patients who had 
died by this time obviously could not be studied, but matching could 
be carried out retrospectively upon the nearly 40 reCipients still surviv-
ing from Series I and their donors.w Subsequently, tissue typing 
almost always was carried out in advance of operation. At all times 
the reagents used for typing were lymphocytotoxin-rich human iso-
immune antisera obtained from persons who had been sensitized, acci-
dentally or deliberately, to white cell antigens. 
The cytolysis of test lymphocytes by such antisera indicated the pres-
ence of the same or a similar antigen to that which originally had sen-
sitized the serum donor. Failure of such a reaction implied the absence 
of the antigen. When the lymphocytes of both donor and recipient re-
acted the same to a given antiserum, identity of that antigen was said 
to be present. The absence in a donor of an antigen that was present 
in a recipient was defined as compatibility. When an antigen was found 
in the donor lymphocytes but not in those of the recipient, a mismatch 
existed. Identity of antigens was preferable, compatibility was the next 
most satisfactory condition and the least desirable was an overt mis-
match. 
The number of antisera used for a single typing has been as large as 
200. Even when human typing was first performed, it was appreciated 
that many of the antisera in the total panel measured the same or simi-
lar lymphocyte antigens. Between 1963 and 1968, Terasaki and other 
workers in this field, by direct testing and by computer technics, classi-
fied those antisera according to their specificity of action. In this way it 
eventually became possible to define human lymphocyte HL-A anti-
gens against which groups of antisera reacted.43 • 2,')6 
Since tissue typing was performed on our patients before as wen as 
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after the definition of these HL-A groups, it was necessary to convert 
the year-to-year data into unifom1 terminology. This was done in De-
cember, 1969, and January, 1970, by re-analyzing the results obtained 
with the original antisera in the cases of Series I-III and converting the 
findings into HL-A designations. It was possible to define at least eight 
antigenic groups, and at the time of the most completely studied later 
cases, 11 groups (phenotypes) could be identified. 
With the definition of antigen phenotype groups a histocompatibility 
grade (A-E) could be given. An A match indicated identity of all of 
the measured dopor and recipient HL-A antigen groups. With a B 
match no incompatibilities were present, but there were one or more 
examples of non-identity. C, D and E matches were progressively less 
satisfactory, with frank mismatches of one, two or more antigen 
groups. Because new HL-A groups were discovered and characterized 
throughout the 6-year period of analysis, the basis for grading was 
more complete, and consequently more accurate, at the end of the 
study than at the beginning. 
HL-A CORRELATIONS 
By 1970, the case material with a reasonable period of follow-up 
that had become availahle for analysis from our center consisted of 
Series I-III. The retrospective typing for Series I was incomplete. For 
Series II the typing was performed in advance and actually was used 
systematically as an instrument of donor selection in the first such 
clinical trial ever attempted. 259 As it became obvious that a quantum 
improvement in results was not going to be achieved (see Figure 3), 
less and less credence was given to the typing reports even though these 
were always available; thus, in Series III the selection was allowed to 
return to a more or less random process with the exception of sibling 
cases, in which an A match was still considered a significant advantage. 
In late 1969 and the spring of 1970, we and Terasaki undertook a 
total re-evaluation of the HL-A typing versus the clinical and histo-
pathologic outcome in the Colorado Series I-IIl.247 After inter-sibling 
transplantation the recipients of A-matched kidneys had bettcr average 
renal function and a slightly increased long-tcrm survival. In addition, 
the incidence and severity of histopathologic abnormalities in the 
A-matched sibling transplants were minimal. With parent-to-offspring 
transplantation or with transplantation between more distant relatives 
or nonrelated people, no correlation existed between the A-E pheno-
type matching grades and survival, function or histopathology. These 
discouraging results were presented to the American Society of Ne-
phrology in December, 1969, and to the American Surgical Associa-
tion in April, 1970.247 
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At the International Transplantation Society meeting in September, 
1970, qera~aki otTered the same conclusiun of poor HL-A correlation 
in all but perfectly matched siblings on the basis of more than 1,300 
cases compiled from many centers.1 S:! A storm of protest, mainly from 
typers of the European community, greeted Terasaki's presenta-
tion. 61 • 94. llo. 269 However, in the ensuing 3 years, Terasaki's conclu-
sions have become more ancl more accepted, even by some of his for-
mer critics. 1I3 • 169. 180.26, The consequence has been a dampening of 
enthusiasm for kidney shipping schemes in which the traffic of pre-
served cadaveric organs from city to city and center to center was 
envisioned to be controlled by the results of HL-A typing. Today, the 
only authority who continues to make unequivocal claims about the 
value of HL-A matching for unrelated cases is Dausset. 45 
POSSIBLE EXPLANATIONS 
From a biologic viewpoint the most significant positive fact from 
correlation studies was that the designation of an A match endowed a 
slight advantage in terms of survival and quality of homograft function 
as well as a highly significant advantage in terms of the histopathologic 
appearance of the kidneys at varying times postoperatively. In practical 
fact, the designation of an A match in sibling cases almost always was 
an indication that both the donor and the recipient had the same two 
histocompatibility haplotypes, one from each parent, and had, there-
fore, achieved total identity of the HL-A antigens; for the HL-A chro-
mosome it thus could be said that there was genotype as well as pheno-
type identity. These observations supported the conclusions from other 
skin or renal transplantations studied within families about the rele-
vance of HL-A antigens to histocompatibility.3. 30. 2G8 
Several factors could have contributed, perhaps cumulatively, to the 
failure to find significant relationships between the matching grades and 
survival, function or histopathology in all other kinds of cases. One 
such possibility would be "immunologic artefact" caused by the trans-
mission of pre-existing host glomerulonc:phritis to the transplant (see 
section of histopathology). Other reasonable speculations could be 
that (1) the completeness and/or accuracy with which HL-A pheno-
types currently can be measured are substantially poorer than is gen-
erally realized, (2) variable host immunologic reactivity in different 
patients112 • 171. 267. 283 was comparable in importance to the antigen 
match in determining the outcome or (3) host presensitization to anti-
gens present in the homografts jeopardized the outcome in a number 
of instances but was not always recognized as a factor (see preceding 
section on hyperacute rejection). The latter two possibilities recently 
have loomed so large in the perspective of some transplant centers that 
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against a significant percentage of a panel of lymphocy:es from human 
donors is considered a contraindication to transplantation even though 
these antibodies do not react with the lymphocytcs of the prospective 
donor.283 
However, the most important reason for the poor correlations may 
well be the obvious one that the HL-A antigen analysis as presently 
performed provides a woefully incompget~ evaluation of histocompati-
bility. For example, the HL-A genes might not be the only one~ of 
importance in human histocompatibility matching, but could be Situ-
ated on the same chromosome as even more important genes. They 
would then be inherited together within families and thus would serve 
as meanim:ful indicators for the selection of A-match sibling trans-
plants but inadequate markers in other genetic situations.7 
In the search for other means of donor-recipient selection, mixed 
leukocyte culture (MLC) matching has been evaluated ext~nsive!yI 
experimentally and clinically. Good correlation between the mtenslty 
of stimulation and transplant survival has been obtained by somes. 11, 
36,108 but not al!291 observers. "One-way MLC matching" is thought to 
measure the ma!witude of the cellular immunologic response of the 
recipient against ~donor cell antigens. The presence of blocking serum 
factors in the recipient also can be evaluated with MLc.zU2 , 221 At pres-
ent the test is too time consuming-requiring 2 or 3 days for comple-tio~-for convenient pre-transplantation evaluation in cadaveric kid-
ney transplantation. 
Recently, there has been much discussion suggesting that although 
the genes controlling HL-A and MLC reactivity in human beings are 
on the same chromosome, they are distinct and not necessarily parallel 
in their manifestations.' In experimental rodent models the nature of 
the major histocompatibility complex has been well mapped out. In 
mice two serologically defined loci on the main histocompatibility chro-
mosome (H-2D and H-2K) are of major importance and are probably 
comparable to the HL-A loci in man. On the same mouse chromosome 
there are also other lymphocyte-defined loci of major histocompatibil-
ity importance controlling MLC reactivity (such as the Ir locus) situ-
ated between the H-2D and H-2K regions. If analogous complexities 
exist in man, adequate tissue matching apparently will require MLC 
determination as well as HL-A typing, probably as well as other tests 
that have yet to be devised. With each such new ramification the poten-
tial practical value of tissue typing will be diminished, particularly in 
cadaver cases, since the statistical probability of achieving a good 
match bv all criteria will be progressively less. At the moment, the 
single m~st discriminating predictor of success or fail~re \vould appe?r 
to be the MLC. Consequently, development of a rapid MLC test Will 
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provide a potentially valuable tool fur recipient selection in cadaveric 
cases. 
OUR PRESENT POLICIES 
When familial donors arc being screened. priority is given to a sib-
ling with an A match, and an effort is made by genetic mapping of 
other family members to establish that the A match represents a geno-
type, as distinguished from a phenotype. identity. In all other familial 
combinations the quality of the HL-A match no longer is given major 
consideration. Rather, the decision about who is to be the donor is 
made on social, vocational or general medical grounds. Similarly, 
cadaveric organs are distributed to recipients on the basis of ABO 
type and need, rather than by the results of a search for an HL-A 
match. If all other conditions were equal, we still would give an organ 
to a recipient with a good HL-A match versus a poor one, but such a 
choice rarely presents itself. 
The only absolute immunologic contraindication to either intra-
familial or cadaveric transplantation in our center is the demonstration 
of preformed antidonor humoral antibodies. If a prospective recipient 
has antibodies against third-party lymphocytes but not against the 
lymphocytes of the donor, we proceed even though the risk of failure 
apparently is increased thereby. We believe that refusal to treat these 
higher-risk patients will deprive many of effective palliation and will 
flood dialysis facilities with an unacceptably high proportion of the 
end-stage uremic population. 
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